Secretome Therapeutics, a Dallas, TX-based biotechnology company advancing therapies derived from neonatal cardiac progenitor cells (nCPCs), raised $20.4M in funding.
Backers were not disclosed.
The company intends to use the funds to support operations through mid-2026 and fund key initiatives, including:
- Clinical trials: Launching two Phase 1 trials of STM-01 in HFpEF (heart failure with preserved ejection fraction) and DCM (dilated cardiomyopathy), with data expected in Q3 2025.
- Manufacturing scale-up: Transitioning STM-01 manufacturing to 3-dimensional bioreactor technology.
- Pipeline development: Advancing STM-21 and other preclinical programs to address inflammatory conditions.
- Regulatory engagement: Defining the regulatory pathway for STM-01 in orphan indications.
- Intellectual property: Submitting patents on new cell and secretome products following the issuance of composition patents for STM-01 and STM-21.
Led by CEO and President Vinny Jindal, Secretome Therapeutics is developing therapies derived from neonatal cardiac progenitor cells (nCPCs) to address life-threatening cardiovascular diseases and conditions driven by inflammation. Its lead drug is STM-01, a first-in-class cellular therapy designed to reduce inflammation, inhibit fibrosis, and support tissue repair in DCM and HFpEF. It is also developing STM-21, a secretome-based therapeutic in preclinical development for inflammatory conditions, including skin wounds and co-morbidities of diabetes.
FinSMEs
25/11/2024